Literature DB >> 27105663

Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum.

Alberto Serrano-Pozo1, Jing Qian1, Alona Muzikansky1, Sarah E Monsell1, Thomas J Montine1, Matthew P Frosch1, Rebecca A Betensky1, Bradley T Hyman2.   

Abstract

The 2012 neuropathological criteria for the diagnosis of Alzheimer disease (AD) summarize the extent of AD neuropathological change with an ABC score, which is a composite of the Thal stage of amyloid deposition (A), the Braak stage of neurofibrillary tangles (NFTs) (B), and the CERAD neuritic plaque score (C). NFTs and neuritic plaques are well-established contributors to cognitive impairment, but whether the Thal amyloid stage independently predicts antemortem cognition remains unknown. We used the National Alzheimer's Coordinating Center autopsy data set to build adjacent-categories logit regression models with CDR-SOB and Mini-Mental State Examination (MMSE) scores as cognitive outcome variables. Increasing CERAD scores were independently associated with higher CDR-SOB scores, whereas increasing Braak NFT stages predicted both higher CDR-SOB and lower MMSE scores. Increasing Thal amyloid stages were not significantly independently associated with either outcome measure. Increasing ABC scores predicted higher CDR-SOB and lower MMSE scores. These results raise the possibility that Thal amyloid stages do not substantially contribute to predicting antemortem cognition compared to CERAD neuritic plaque scores and Braak NFT stages, and suggest that the diffuse amyloid deposits participating in the assignment of Thal amyloid stages are neutral with respect to clinically detectable cognitive and functional changes.
© 2016 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  ABC score; Alzheimer disease; Amyloid plaques; National Alzheimer’s Coordinating Center; Neuritic plaques; Neurofibrillary tangles; Thal stages.

Mesh:

Year:  2016        PMID: 27105663      PMCID: PMC6250207          DOI: 10.1093/jnen/nlw026

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  37 in total

1.  "Preclinical" AD revisited: neuropathology of cognitively normal older adults.

Authors:  F A Schmitt; D G Davis; D R Wekstein; C D Smith; J W Ashford; W R Markesbery
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Microglial activation in early stages of amyloid beta protein deposition.

Authors:  A Sasaki; H Yamaguchi; A Ogawa; S Sugihara; Y Nakazato
Journal:  Acta Neuropathol       Date:  1997-10       Impact factor: 17.088

3.  Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease.

Authors:  R E Mrak; J G Sheng; W S Griffin
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

4.  Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.

Authors:  T Suenaga; A Hirano; J F Llena; H Ksiezak-Reding; S H Yen; D W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  1990-01       Impact factor: 3.685

5.  Quantitative synaptic alterations in the human neocortex during normal aging.

Authors:  E Masliah; M Mallory; L Hansen; R DeTeresa; R D Terry
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

Review 6.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

Review 8.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.

Authors:  Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

9.  A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis.

Authors:  Susana Boluda; Jon B Toledo; David J Irwin; Kevin M Raible; Matt D Byrne; Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-06-12       Impact factor: 17.088

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  25 in total

1.  Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy.

Authors:  Lilah M Besser; John F Crary; Charles Mock; Walter A Kukull
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

2.  Correlations Between Single Nucleotide Polymorphisms, Cognitive Dysfunction, and Postmortem Brain Pathology in Alzheimer's Disease Among Han Chinese.

Authors:  Qian Yang; Kang Chen; Hanlin Zhang; Wanying Zhang; Changlin Gong; Qing Zhang; Pan Liu; Tianyi Sun; Yuanyuan Xu; Xiaojing Qian; Wenying Qiu; Chao Ma
Journal:  Neurosci Bull       Date:  2019-02-19       Impact factor: 5.203

3.  Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells.

Authors:  Amanda L Woerman; Atsushi Aoyagi; Smita Patel; Sabeen A Kazmi; Iryna Lobach; Lea T Grinberg; Ann C McKee; William W Seeley; Steven H Olson; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-28       Impact factor: 11.205

4.  Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples.

Authors:  Willa D Brenowitz; C Dirk Keene; Stephen E Hawes; Rebecca A Hubbard; W T Longstreth; Randy L Woltjer; Paul K Crane; Eric B Larson; Walter A Kukull
Journal:  Neurobiol Aging       Date:  2017-01-30       Impact factor: 4.673

5.  Effects of Chronic Arginase Inhibition with Norvaline on Tau Pathology and Brain Glucose Metabolism in Alzheimer's Disease Mice.

Authors:  Baruh Polis; Margherita Squillario; Vyacheslav Gurevich; Kolluru D Srikanth; Michael Assa; Abraham O Samson
Journal:  Neurochem Res       Date:  2022-01-31       Impact factor: 3.996

6.  Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment.

Authors:  Cécilia Tremblay; Geidy E Serrano; Anthony J Intorcia; Monica R Mariner; Lucia I Sue; Richard A Arce; Alireza Atri; Charles H Adler; Christine M Belden; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2022-07-19       Impact factor: 3.148

7.  Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials.

Authors:  Maura Malpetti; Renaud La Joie; Gil D Rabinovici
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

8.  Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies.

Authors:  David J Koss; Daniel Erskine; Andrew Porter; Pawel Palmoski; Hariharan Menon; Olivia G J Todd; Marta Leite; Johannes Attems; Tiago F Outeiro
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

9.  Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Authors:  Sara Hall; Christina D Orrù; Byron Caughey; Oskar Hansson; Geidy E Serrano; Douglas Galasko; Andrew G Hughson; Bradley R Groveman; Charles H Adler; Thomas G Beach
Journal:  Acta Neuropathol Commun       Date:  2022-06-22       Impact factor: 7.578

10.  Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme.

Authors:  Michael L Alosco; Jonathan D Cherry; Bertrand Russell Huber; Yorghos Tripodis; Zachary Baucom; Neil W Kowall; Nicole Saltiel; Lee E Goldstein; Douglas I Katz; Brigid Dwyer; Daniel H Daneshvar; Joseph N Palmisano; Brett Martin; Robert C Cantu; Robert A Stern; Victor E Alvarez; Jesse Mez; Thor D Stein; Ann C McKee
Journal:  Acta Neuropathol       Date:  2020-08-11       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.